Current Proceedings of Cerebral Palsy

Author:

Fan Hueng-Chuen1,Ho Li-Ing2,Chi Ching-Shiang3,Cheng Shin-Nan3,Juan Chun-Jung4,Chiang Kuo-Liang5,Lin Shinn-Zong6,Harn Horng-Jyh7

Affiliation:

1. Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

2. Department of Respiratory Care, Veterans General Hospital-Taipei, Taiwan

3. Department of Pediatrics, Tung's Taichung Metroharbor Hospital, Wuchi, Taichung, Taiwan

4. Department of Chest Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

5. Department of Pediatric Neurology, Kuang-Tien General Hospital, Shalu, Taichung, Taiwan

6. Center for Neuropsychiatry, China Medical University and Hospital and Beigang Hospital, Taichung and Yun-Lin, Taiwan

7. Department of Pathology, China Medical University and Hospital, Taichung, Taiwan

Abstract

Cerebral palsy (CP) is a complicated disease with varying causes and outcomes. It has created significant burden to both affected families and societies, not to mention the quality of life of the patients themselves. There is no cure for the disease; therefore, development of effective therapeutic strategies is in great demand. Recent advances in regenerative medicine suggest that the transplantation of stem cells, including embryonic stem cells, neural stem cells, bone marrow mesenchymal stem cells, induced pluripotent stem cells, umbilical cord blood cells, and human embryonic germ cells, focusing on the root of the problem, may provide the possibility of developing a complete cure in treating CP. However, safety is the first factor to be considered because some stem cells may cause tumorigenesis. Additionally, more preclinical and clinical studies are needed to determine the type of cells, route of delivery, cell dose, timing of transplantation, and combinatorial strategies to achieve an optimal outcome.

Publisher

SAGE Publications

Subject

Transplantation,Cell Biology,Biomedical Engineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3